This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Scotoma Reduction in AMD Patients Treated With Ranibizumab (SALVAGE)

This study has been completed.
Information provided by:
Retina Research Foundation Identifier:
First received: April 29, 2007
Last updated: July 28, 2011
Last verified: July 2011
This is a trial aimed at patients with advanced wet macular degeneration and macular scarring treated wiht intravitreal injections of Lucentis.

Condition Intervention Phase
Macular Degeneration Drug: intravitreal injection Lucentis (ranibizumab) Phase 1 Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I/II Study to Evaluate Scotoma Reduction in And Limited Visual Acuity in aGe Related Macular Degeneration Patients Treated With Intravitreal Lucentis

Resource links provided by NLM:

Further study details as provided by Retina Research Foundation:

Primary Outcome Measures:
  • scotoma reduction [ Time Frame: 12 months ]

Secondary Outcome Measures:
  • improved visual function [ Time Frame: 12 months ]

Estimated Enrollment: 20
Study Start Date: March 2007
Study Completion Date: November 2007
Primary Completion Date: November 2007 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: intravitreal injection Lucentis (ranibizumab)
    intravitreal injection Lucentis (ranibizumab)
Detailed Description:
Patients with severe wet macular degeneration and scarring in the center of the retina may benefit from treatment if the size of the blind spot is reduced wiht injections of Lucentis.

Ages Eligible for Study:   50 Years to 90 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • BCVA < 20/320
  • Disciform macular degeneration wiht exudation

Exclusion Criteria:

  • Non-amd CNV
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00467935

United States, New York
Retina Research Center
Slingerlands, New York, United States, 12159
Sponsors and Collaborators
Retina Research Foundation
Principal Investigator: Paul M Beer, MD Retina Research Foundation
  More Information

Additional Information:
Responsible Party: Paul Beer, MD, Retina Consultants, PLLC Identifier: NCT00467935     History of Changes
Other Study ID Numbers: FVF3933
Study First Received: April 29, 2007
Last Updated: July 28, 2011

Keywords provided by Retina Research Foundation:

Additional relevant MeSH terms:
Macular Degeneration
Retinal Degeneration
Retinal Diseases
Eye Diseases
Vision Disorders
Sensation Disorders
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Immunologic Factors
Physiological Effects of Drugs
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Growth Inhibitors
Antineoplastic Agents processed this record on August 22, 2017